Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

Inclusion Criteria

Inclusion Criteria

Patients must have:

- AIDS-related Kaposi's sarcoma that requires systemic chemotherapy.

- EITHER a medical indication for continuation of DOX-SL following treatment on another
DOX-SL protocol, OR no remaining treatment options other than DOX-SL.

Prior Medication:

Allowed:

- Prior anthracyclines.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Cardiac ejection fraction < 50 percent or clinically significant cardiac disease.

- Eligibility for a Liposomal Technology comparative protocol.

Concurrent Medication:

Excluded:

- Other cytotoxic chemotherapy.

Patients with the following prior condition are excluded:

History of idiosyncratic or allergic reaction to anthracyclines.

Prior Medication:

Excluded:

- Chemotherapy within the past 3 weeks.